NeuroMetrix Executives

NeuroMetrix Management Team Effectiveness

The company has return on total asset (ROA) of (0.279) % which means that it has lost $0.279 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4538) %, meaning that it created substantial loss on money invested by shareholders. NeuroMetrix's management efficiency ratios could be used to measure how well NeuroMetrix manages its routine affairs as well as how well it operates its assets and liabilities. NeuroMetrix secures 15.08 % of its outstanding shares held by insiders and 18.23 % owned by institutional investors. Some institutional investors establish a significant position in stocks such as NeuroMetrix in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of NeuroMetrix, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

NeuroMetrix Workforce Comparison

The company has Profit Margin (PM) of (2.57) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.36) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.36.

NeuroMetrix Insider Trading

NeuroMetrix Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as NeuroMetrix often depends on how effective the management is. NeuroMetrix management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NeuroMetrix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NeuroMetrix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

If you are still planning to invest in NeuroMetrix check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuroMetrix's history and understand the potential risks before investing.